PharmaEssentia (TPE:6446) clarified a Taiwan's Economic Daily News projecting the company's full-year profit would exceed twice its paid-in capital was media speculation and was not based on any financial or business forecast provided by the company.
The report also said Japan's health ministry expert panel had endorsed expanding BESREMi (Ropeginterferon alfa-2b) to all essential thrombocythemia patients and that approval could come as early as mid-August.
PharmaEssentia said the actual review timeline, approved indication and regulatory outcome in Japan remain subject to an official decision by the country's Ministry of Health, Labour and Welfare.
The company asked investors to only rely on its disclosures on Taiwan's MOPS for official updates.